Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000644814 | SCV000766529 | benign | Amyotrophic lateral sclerosis type 4; Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2022-12-06 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001849022 | SCV002105163 | uncertain significance | Hereditary spastic paraplegia | 2017-01-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002334141 | SCV002642184 | uncertain significance | Inborn genetic diseases | 2021-01-20 | criteria provided, single submitter | clinical testing | The p.H1660R variant (also known as c.4979A>G), located in coding exon 8 of the SETX gene, results from an A to G substitution at nucleotide position 4979. The histidine at codon 1660 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. This alteration has been reported in a heterozygous state in a single patient with familial amyotrophic lateral sclerosis (Müller K et al. J Neurol Neurosurg Psychiatry, 2018 08;89:817-827). In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the supporting evidence, this variant is unlikely to be causative of juvenile amyotrophic lateral sclerosis 4; however, its contribution to the development of spinocerebellar ataxia with axonal neuropathy 2 is uncertain. |
Athena Diagnostics | RCV002473088 | SCV002771070 | uncertain significance | not provided | 2021-12-07 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003233771 | SCV003931347 | uncertain significance | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003233772 | SCV003931348 | uncertain significance | Amyotrophic lateral sclerosis type 4 | 2023-02-08 | criteria provided, single submitter | clinical testing |